Popular Articles

Damon Runyon Cancer Research Foundation Awards Prestigious Fellowships To 17 Top Young Scientists
The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting exceptional early career researchers and innovative cancer research, named 17 new Damon Runyon Fellows at its May 2009 Fellowship Award Committee review. The recipients of this prestigious, three-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. The Fellowship is specifically intended to encourage the nation"s most promising young scientists to pursue careers in cancer research by providing them with independent funding ($140,000 each) to work on innovative projects.
generic viagra online
Novavax Completes Enrollment Of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 influenza season. This clinical trial represents another step in the development of Novavax"s VLP seasonal influenza vaccine, allowing further evaluation of safety and immunogenicity of a broad range of vaccine doses against a new set of influenza strains. As announced in December of 2008, the first Phase II study evaluated a trivalent VLP vaccine against the seasonal influenza strains that circulated in the 2005-2006 influenza season.
News of the day
First Patient Enrolled In Regeneron And Bayer HealthCare VEGF Trap-Eye Phase 3 Program In Central Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the first patient has been enrolled in the Phase 3 program of VEGF Trap-Eye for the treatment of central retinal vein occlusion (CRVO), a leading cause of blindness in adults. Regeneron received a $20 million milestone payment from Bayer Healthcare that was triggered by the dosing of the first patient in the CRVO program. Regeneron also announced that enrollment in the Phase 2 DA VINCI study of VEGF Trap-Eye in diabetic macular edema (DME) has been completed and data are expected during the first half of 2010.
Sexual Health

UCD Researchers Reveal Six New Genome Sequences And Fundamental Insights To The Candida Fungus Family

An international research collaboration coordinated by UCD researchers and involving scientists at 21 institutes including the genome sequencing centres in the Wellcome Trust Sanger Institute, UK and the Broad Institute at MIT and Harvard, USA have defined six new genome sequences in the Candida fungus family and identified genetic differences in species that cause disease. The research, published yesterday in Nature, describes how Candida strains have evolved and ensured their survival by adapting their genetic makeup to respond to changes in their environment. Candida species are the most common cause of opportunistic fungal infection worldwide. The incidence of Candida parapsilosis in particular poses the greatest threat to transplant patients and premature babies as it forms a film that coats the inside of medical devices such as implants, catheters or feeding tubes. The fungus is drug resistant and the only effective treatment involves the removal of the medical device. Prior to this work, very little was known about this species. The UCD research team led by Professor Geraldine Butler from UCD Conway Institute & School of Biomolecular & Biomedical Science looked at key components of mating and cell division in Candida species, shedding new light on how the fungi reproduce and survive. Professor Butler, scientific coordinator on this project, began working to identify the sequence of genes of C. parapsilosis in 2003 through funding from Science Foundation Ireland. She said, "We started by sequencing small parts of the C. parapsilosis genome, which led to our collaboration with the Sanger Institute to sequence the entire genome, and finally to combining this genome with others sequenced by the Broad Institute" Commenting on their findings, Professor Butler says, "Candida species were originally believed to be incapable of mating, and so may have difficulties in adapting to new environments or new hosts. As a result of our analysis, we now know a great deal more about the evolution of mating, and how some species recombine their genes. Interestingly, C. parapsilosis is probably the only species that cannot mate" By comparing the genetic sequences in disease and non-disease causing fungi, the team found that in general, the disease causing Candida species have many more copies of genes involved in adhesion, and in the cell wall. The stickiness of the proteins in the cell wall makes it easier for the fungi to adhere to the human host.. Further research on the regulation of these proteins may lead to developing treatment methods for infections caused by fungi in the future. UCD Conway Institute of Biomolecular & Biomedical Research


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):